Avicanna (TSE:AVCN) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Avicanna has successfully completed its first delivery of proprietary topical products to a multinational pharmaceutical company, marking a significant step in its European commercial expansion. The products, which include CBD and CBG-based formulations, are set to launch in six European countries in 2025, leveraging the pharmaceutical company’s established infrastructure.
For further insights into TSE:AVCN stock, check out TipRanks’ Stock Analysis page.
